paediatrics Brussels 17
|
paed bru 17 |
1 |
|
L1.1 Epidemiology - DW |
1 |
|
L1.2 Imaging in Medulloblastoma and ependymoma – TJ |
75 |
|
L1.3 Ependymoma - general aspects - RDK |
145 |
|
L1.4 Ependymoma - role of RT - BT |
202 |
|
L1.5 Medulloblastoma - general aspects - RT |
279 |
|
L1.6 Medulloblastoma - AP |
353 |
|
L1.7 Normal CNS anatomy - TJ |
423 |
|
L2.1 Chemotherapy in children - DW |
468-469 |
|
L2.2 M. Hodgkin - role of RT - KD |
634 |
|
L2.3 Rhabdomyosarcoma - general aspects and L2.4 Rhabdomyosarcoma -role of RT - AP |
694 |
|
L2.5 Late effects non-CNS tumours - KD |
818 |
|
L2.6 Ewing’s sarcoma I - Clinical features - UR |
884 |
|
L2.7 Ewing’s sarcoma II -Treatment techniques - UR |
952 |
|
L3.1 Nephroblastoma the COG concepts - AP |
1012 |
|
L3.2 Nephroblastoma the SIOP concepts - RT |
1090 |
|
L3.3 RT in Neuroblastoma - CC |
1143 |
|
L3.4 IMRT in children - CC |
1194 |
|
L3.5 Proton therapy in childhood tumours CNS - BT |
1235 |
|
L3.6 Proton therapy in childhood tumours non-CNS - BT |
1295 |
|
A1 The ESTRO School_Ricardi PROS |
1345 |
|
C2.1 Case discussion - medulloblastoma - CV |
1377 |
|
epend |
1414 |
|
Ependymoma Merchant-intracranial-up-date-Lancet-2009-20-06-2009 |
1414 |
|
Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study |
1414 |
|
Introduction |
1414 |
|
Methods |
1415 |
|
Patients |
1415 |
|
Surgery and imaging follow-up |
1415 |
|
Conformal radiotherapy |
1415 |
|
Statistical analysis |
1415 |
|
Role of the funding source |
1416 |
|
Results |
1416 |
|
Discussion |
1419 |
|
Acknowledgments |
1421 |
|
References |
1421 |
|
Ependymoma-Andreiuolo-Integrating Tenascin-C protein expression-17.10.2017 |
1423 |
|
Ependymoma-Conter-SFOP-hfx-ependymoma-29-09-2009 |
1440 |
|
Intracranial Ependymomas in Children: Society of Pediatric Oncology Experience with Postoperative Hyperfractionated Local Radiotherapy |
1440 |
|
Introduction |
1440 |
|
Patients and Methods |
1441 |
|
Patient eligibility |
1441 |
|
Treatment characteristics |
1441 |
|
Evaluation procedures |
1441 |
|
Statistical analysis |
1441 |
|
Results |
1441 |
|
Study population |
1441 |
|
Surgery |
1441 |
|
Central radiologic review |
1442 |
|
Radiotherapy |
1442 |
|
PFS and OS |
1442 |
|
Prognostic factors analysis |
1442 |
|
Patterns of failure |
1442 |
|
Long-term side effects |
1443 |
|
Discussion |
1443 |
|
Conclusion |
1445 |
|
References |
1445 |
|
Ependymoma-Grundy-UKCCSG-chemo-only |
1447 |
|
Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study |
1447 |
|
Introduction |
1447 |
|
Methods |
1448 |
|
Participants |
1448 |
|
Procedures |
1448 |
|
Assessment |
1449 |
|
Statistical analysis |
1449 |
|
Role of the funding source |
1450 |
|
Results |
1450 |
|
Discussion |
1453 |
|
Acknowledgments |
1455 |
|
References |
1455 |
|
Ependymoma-MacDonald-proton therapy |
1457 |
|
Proton Radiotherapy for Childhood Ependymoma: Initial Clinical Outcomes and Dose Comparisons |
1457 |
|
Introduction |
1457 |
|
Methods and Materials |
1458 |
|
Patients |
1458 |
|
Dosimetric comparisons |
1458 |
|
Statistical analysis |
1458 |
|
Ethical considerations |
1459 |
|
Results |
1459 |
|
Discussion |
1461 |
|
References |
1464 |
|
Ependymoma-MacDonald-proton-28-07-2008 |
1465 |
|
Proton Radiotherapy for Childhood Ependymoma: Initial Clinical Outcomes and Dose Comparisons |
1465 |
|
Introduction |
1465 |
|
Methods and Materials |
1466 |
|
Patients |
1466 |
|
Dosimetric comparisons |
1466 |
|
Statistical analysis |
1466 |
|
Ethical considerations |
1467 |
|
Results |
1467 |
|
Discussion |
1469 |
|
References |
1472 |
|
Ependymoma-Massimino 2016 final results AIEOP-Protocol intracran. ependymoma 13.09.2017 |
1473 |
|
Ependymoma-Massimino-hfx-AEIOP-SIOP |
1483 |
|
HYPERFRACTIONATED RADIOTHERAPY AND CHEMOTHERAPY FOR CHILDHOOD EPENDYMOMA: FINAL RESULTS OF THE FIRST PROSPECTIVE AIEOP (ASSOCIAZIONE ITALIANA |
1483 |
|
INTRODUCTION |
1484 |
|
METHODS AND MATERIALS |
1484 |
|
Patient eligibility |
1484 |
|
Pathology review |
1484 |
|
Surgery and staging |
1484 |
|
Treatment regimens |
1485 |
|
Statistical analyses |
1485 |
|
RESULTS |
1485 |
|
Patients |
1485 |
|
Tumor location |
1485 |
|
Extent of resection |
1486 |
|
Histology |
1486 |
|
Treatment feasibility and compliance |
1486 |
|
Compliance in patients without residual tumor |
1486 |
|
Compliance in patients with residual tumor |
1487 |
|
Response to chemotherapy |
1487 |
|
Chemotherapy toxicity |
1487 |
|
Second-look surgery |
1487 |
|
Overall survival and progression-free survival |
1487 |
|
Survival analyses |
1487 |
|
DISCUSSION |
1488 |
|
REFERENCES |
1491 |
|
Ependymoma-McGuire-intracranial-spinal-SEER-analysis-20-06-2009 |
1493 |
|
Ependymoma-Merchant-intracranial-sites-review-20-06-2009 |
1498 |
|
Three-dimensional conformal radiation therapy for ependymoma |
1498 |
|
Abstract |
1498 |
|
Abstract |
1498 |
|
Abstract |
1498 |
|
Purpose |
1498 |
|
Materials and methods |
1499 |
|
Result |
1502 |
|
IMRT |
1502 |
|
FSRT |
1503 |
|
SRS |
1503 |
|
Craniospinal RT |
1503 |
|
Conclusion |
1504 |
|
References |
1504 |
|
Ependymoma-Merchant-preliminary-3D-with neurocog- |
1506 |
|
Ependymoma-Merchant-re-irradiation- |
1513 |
|
A Retrospective Study of Surgery and Reirradiation for Recurrent Ependymoma |
1513 |
|
Introduction |
1513 |
|
Patients and Methods |
1513 |
|
RT2 techniques |
1514 |
|
Analysis |
1514 |
|
Definitions |
1514 |
|
Results |
1514 |
|
Study group |
1514 |
|
RT1: initial irradiation |
1515 |
|
Failure after RT1 and treatment before RT2 |
1515 |
|
RT2: radiosurgery |
1515 |
|
RT2: FFRT |
1518 |
|
RT2: CSI |
1519 |
|
Discussion |
1520 |
|
References |
1522 |
|
Ependymoma-Pajtler-The current consensus on the clinical management-17.10.2017 |
1524 |
|
The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants |
1524 |
|
Abstract |
1524 |
|
Introduction |
1525 |
|
The utility of histologic grading of ependymoma in a molecular era |
1525 |
|
Molecular subgroups of ependymal tumors in the central nervous system |
1526 |
|
Clinical management of intracranial ependymoma in the context of molecular subgroups |
1527 |
|
Model development and novel therapeutics |
1529 |
|
Conclusions |
1529 |
|
Acknowledgements |
1529 |
|
References |
1530 |
|
Ependymoma-Ramaswamy-ependymoma-new-molc-groups-survival-JCO-2016-20-06-2016 |
1532 |
|
Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospec ... |
1532 |
|
INTRODUCTION |
1440 |
|
METHODS |
1441 |
|
RESULTS |
1441 |
|
Demographics of Posterior Fossa Ependymoma Cohorts |
1441 |
|
Subgroup Affiliation Is the Most Powerful Prognostic Marker for Posterior Fossa Ependymoma |
1441 |
|
EPN_PFA Carries a Poor Prognosis Independent of Age at Diagnosis |
1441 |
|
Surgical Cytoreduction of EPN_PFA Is Prognostic Independent of Subgroup |
1441 |
|
Patients With GTR EPN_PFB Have an Excellent Prognosis |
1441 |
|
DISCUSSION |
1443 |
|
REFERENCES |
1540 |
|
Acknowledgment |
1545 |
|
Appendix |
1545 |
|
Methods |
1545 |
|
Ependymoma-Reni-review-17-04-2009 |
1555 |
|
Ependymoma |
1555 |
|
General information |
1556 |
|
Definition |
1556 |
|
Incidence |
1556 |
|
Survival |
1556 |
|
Aetiology and risk factors |
1556 |
|
Pathology and biology |
1556 |
|
Histopathology |
1556 |
|
Myxopapillary ependymoma (WHO grade I) |
1557 |
|
Subependymoma (WHO grade I) |
1557 |
|
Ependymoma (WHO grade II) |
1557 |
|
Anaplastic ependymoma (WHO grade III) |
1557 |
|
Immunophenotype |
1557 |
|
Immunophenotype |
1557 |
|
Genetic features |
1557 |
|
Genetic features |
1557 |
|
Diagnosis |
1557 |
|
Clinical presentation |
1557 |
|
Localisation |
1557 |
|
Diagnostic criteria |
1558 |
|
Staging |
1558 |
|
Staging procedures |
1558 |
|
Staging system |
1558 |
|
Restaging procedures |
1558 |
|
Prognosis |
1558 |
|
Natural history |
1558 |
|
Prognostic factors |
1558 |
|
Treatment |
1559 |
|
Surgery |
1559 |
|
Radiation therapy |
1559 |
|
Chemotherapy |
1560 |
|
Treatment of recurrent disease |
1560 |
|
New active drugs and therapeutic options |
1560 |
|
Late sequelae |
1561 |
|
Long term sequelae |
1561 |
|
Follow-up |
1561 |
|
Follow up |
1561 |
|
Acknowledgment |
1561 |
|
References |
1561 |
|
Ependymoma-spinal-canal-Akyurek-myxopapillary subtype |
1564 |
|
Ependymoma-spinal-canal-Schild-Mayo-Clinic experience |
1571 |
|
Ependymoma-spinal-canal-Wahab-postop-RT |
1577 |
|
Long term outcome with post-operative radiation therapy for spinal canal ependymoma |
1577 |
|
Abstract |
1577 |
|
Introduction |
1577 |
|
Methods and materials |
1578 |
|
Results |
1578 |
|
Discussion |
1579 |
|
Conclusions |
1580 |
|
Acknowledgement |
1580 |
|
References |
1580 |
|
Ependymoma-Taylor-review-doses-volumes-06-07-2009 |
1582 |
|
Ependymoma-Timmermann-HIT91 |
1586 |
|
Ependymoma-Timmermann-HIT-SKK |
1595 |
|
Role of radiotherapy in anaplastic ependymoma in children under age of 3 years: Results of the prospective German brain tumor trials HIT-SKK 87 and 92 |
1595 |
|
Materials and methods |
1595 |
|
Patient eligibility |
1596 |
|
Evaluation of disease |
1596 |
|
Evaluation of toxicity and quality of life |
1596 |
|
Treatment protocol |
1596 |
|
Statistical considerations |
1597 |
|
Results |
1597 |
|
Patient population |
1597 |
|
Treatment |
1598 |
|
Survival |
1598 |
|
Patterns of failure |
1598 |
|
Late effects |
1598 |
|
Prognostic factors |
1599 |
|
Discussion |
1599 |
|
Conclusion |
1601 |
|
References |
1601 |
|
Ependymoma-von-Hoff-neurocog-outcome-IGR-20-06-2009 |
1603 |
|
Abstract |
1603 |
|
Background |
1603 |
|
Methods |
1603 |
|
Results |
1603 |
|
Conclusion |
1603 |
|
Background |
1603 |
|
Methods |
1604 |
|
Patients |
1604 |
|
Radiotherapy |
1604 |
|
Neuropsychologic evaluation |
1605 |
|
Statistical Analysis |
1605 |
|
Results |
1605 |
|
Profile of neuropsychological evaluation |
1606 |
|
Risk factor analysis (see table |
1606 |
|
Age |
1606 |
|
Interval since RT and FSIQ |
1606 |
|
Cerebellar syndrome and other influencing factors |
1607 |
|
Schooling |
1608 |
|
Endocrine deficits |
1608 |
|
Discussion |
1608 |
|
Conclusion |
1609 |
|
Competing interests |
1609 |
|
Authors' contributions |
1609 |
|
References |
1610 |
|
Pre-publication history |
1611 |
|
Ependymom-Subtyping-review-27-10-2017 |
1612 |
|
late effects |
1613 |
|
Late-effects-Camara-Costa-PNET-4-neurocog-03-08-2016 |
1613 |
|
Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlle ... |
1621 |
|
Introduction |
1614 |
|
Methods and Materials |
1615 |
|
Patients |
1615 |
|
Procedure |
1615 |
|
Measurements |
1615 |
|
Statistical analysis |
1615 |
|
Results |
1615 |
|
Group comparisons between participants and nonparticipants |
1639 |
|
Demographic and baseline characteristics for participants |
1441 |
|
Cognitive outcomes at posttreatment evaluation for the whole group of participants |
1442 |
|
Effects of treatment on cognitive outcomes |
1442 |
|
Longitudinal analyses |
1442 |
|
Discussion |
1445 |
|
Conclusions |
1619 |
|
References |
1619 |
|
Late-effects-Kennedy-PNET-IV-QoS-2014-09-01-2014 |
1621 |
|
Quality of Survival and Growth in Children and Young Adults in the PNET4 European Controlled Trial of Hyperfractionated Ver ... |
1621 |
|
Introduction |
1622 |
|
Methods and Materials |
1622 |
|
Patients |
1615 |
|
Procedure |
1622 |
|
Outcome measures |
1623 |
|
Statistical analysis |
1623 |
|
Results |
1623 |
|
Baseline characteristics |
1623 |
|
Outcomes at posttreatment evaluation |
1623 |
|
Effect of HFRT on executive function, behavior, health status, and HRQoL |
1623 |
|
Effect of HFRT on growth |
1623 |
|
Impact of demographic characteristics and clinical events |
1624 |
|
Hormone and other therapies, ototoxicity, and adult social and employment outcomes |
1442 |
|
Discussion |
1625 |
|
References |
1628 |
|
Late-effects-Merchant-endocrinol-deficits-3-d-conf-JCO-2011-03-12-2013 |
1630 |
|
Late-effects-Merchant-IQ modeling-medulloblastoma-2014-08-10-2014 |
1635 |
|
Critical Combinations of Radiation Dose and Volume Predict Intelligence Quotient and Academic Achievement Scores After Cran ... |
1635 |
|
Introduction |
1636 |
|
Methods and Materials |
1636 |
|
Results |
1637 |
|
Longitudinal trends in cognitive scores |
1637 |
|
Impact of clinical variables on longitudinal trends in cognitive scores |
1637 |
|
Impact of mean radiation dose on longitudinal trends in cognitive scores |
1615 |
|
TD 50/5 for below-average IQ and academic achievement according to mean normal tissue dose |
1639 |
|
Impact of radiation dose intervals on longitudinal trends in cognitive scores |
1639 |
|
TD 50/5 for below-average IQ and academic achievement according to radiation dose intervals |
1639 |
|
Discussion |
1640 |
|
References |
1642 |
|
Late-effects-Merchant-IQ-cerebellum-dose-2014-08-10-2014 |
1643 |
|
Effect of Cerebellum Radiation Dosimetry on Cognitive Outcomes in Children With Infratentorial Ependymoma |
1643 |
|
Introduction |
1622 |
|
Methods and Materials |
1644 |
|
Patients |
1644 |
|
Radiation treatment planning, cerebellar contouring, and radiation dose |
1644 |
|
Surgery and chemotherapy |
1645 |
|
Cognitive outcomes intelligence quotient, academic tests, and visual-auditory learning scores |
1645 |
|
Statistical analysis |
1645 |
|
Results |
1645 |
|
Effect of cerebellar dosimetry on longitudinal IQ scores |
1646 |
|
Effect of cerebellar dosimetry on longitudinal WIAT reading, math, and spelling scores |
1646 |
|
Effect of tumor volume, surgery, and RT parameters |
1646 |
|
Discussion |
1647 |
|
Conclusions |
1648 |
|
References |
1648 |
|
Late-effects-Moxon-Emre-Bouffet-Laperriere-JCO-2014-16-02-2015 |
1650 |
|
Late-effects-Netson-ependymoma-functioning-st-Jude-28-05-2013 |
1660 |
|
A 5-Year Investigation of Children’s Adaptive Functioning Following Conformal Radiation Therapy for Localized Ependymoma |
1660 |
|
Introduction |
1661 |
|
Methods and Materials |
1661 |
|
Participants |
1661 |
|
Medical treatment and clinical factors |
1662 |
|
Neurocognitive assessment |
1662 |
|
Analyses |
1663 |
|
Results |
1663 |
|
Discussion |
1664 |
|
Conclusions |
1665 |
|
References |
1666 |
|
Supplementary Material |
1667 |
|
Late-effects-Packer-survival-secondary-tumours-COG-A9961-31-03-2014 |
1668 |
|
Late-effects-Palmer-Medulloblastoma-neurocog-St-Jude-JCO-2013-16-01-2014 |
1675 |
|
Late-effects-Redmond-hippocampus-dose-neurocog-march-2013-25-08-2014 |
1685 |
|
Late-effects-Ris-intellectual.outcome-2-diff-chx-COG-A9961-2013-31-03-2014 |
1695 |
|
Late-effects-Uh-Merchant-2013 Differences in brainstem areas to RT-01-02-2016 |
1703 |
|
Differences in Brainstem Fiber Tract Response to Radiation: A Longitudinal Diffusion Tensor Imaging Study |
1660 |
|
Introduction |
1703 |
|
Methods and Materials |
1704 |
|
Participants |
1704 |
|
Treatment |
1704 |
|
MRI data acquisition |
1704 |
|
Image processing |
1615 |
|
Volumes of interest |
1705 |
|
Statistical analysis |
1705 |
|
Results |
1705 |
|
Discussion |
1707 |
|
References |
1708 |